Sommerer, Claudia
,
Witzke, Oliver
Lehner, Frank
Arns, Wolfgang
Reinke, Petra
Eisenberger, Ute
Vogt, Bruno
Heller, Katharina
Jacobi, Johannes
Guba, Markus
Stahl, Rolf
Hauser, Ingeborg A.
Kliem, Volker
Wüthrich, Rudolf P.
Mühlfeld, Anja
Suwelack, Barbara
Duerr, Michael
Paulus, Eva-Maria
Zeier, Martin
Porstner, Martina
Budde, Klemens
Funding for this research was provided by:
Novartis Pharma (The ZEUS and HERAKLES studies were funded by Novartis Pharma GmbH, Nürnberg, Germany. The company contributed to the design of the study and to the analysis of data, and reviewed the manuscript before submission. All data collection was undertaken by the investigators.)
Article History
Received: 29 August 2017
Accepted: 31 August 2018
First Online: 19 September 2018
Ethics approval and consent to participate
: All patients provided written informed consent. The study protocols were conducted in compliance with German law and approved by the independent ethics committee or institutional review board for each center, and the procedures followed in the trials were in accordance with the Declaration of Helsinki 1975, as revised in 2008.
: Not applicable.
: Claudia Sommerer has received honoraria from Novartis, Chiesi and Sanofi, and her institution has received research funding from Chiesi, Astellas and Novartis.Oliver Witzke has received research funds and/or honoraria from Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Janssen-Cilag, MSD, Novartis, Pfizer, Roche and Shire.Frank Lehner has received research funds and/or honoraria from Astellas, Bristol-Myers Squibb, Chiesi, Fresenius, Hexal, Novartis, Pfizer and Roche Pharma.Wolfgang Arns has received research funds and/or honoraria from Alexion, Astellas, Chiesi and Novartis.Petra Reinke has received research funds, honoraria, advisory board from Teva, ThermoFisher, Pfizer, Astellas, Amgen, Baxalta; MSD and Pluriste.Ute Eisenberger has received honoraria and/or travel expenses from Novartis Pharma, Astellas and Amgen.Bruno Vogt has no conflicts of interest to declare.Katharina Heller has no conflicts of interest to declare.Johannes Jacobi has received honoraria from Roche.Markus Guba has no conflicts of interest to declare.Rolf Stahl has no conflicts of interest to declare.Ingeborg A Hauser has received honoraria from Alexion, Astellas, Chiesi, Fresenius, Hexal, Novartis, Roche, Sanofi and Teva.Volker Kliem has received honoraria and fees from Astellas, Novartis, Raptor and Fresenius.Rudolf P Wüthrich has received fees for scientific advice from Astellas, Novartis, Roche and Wyeth (now Pfizer).Anja Mühlfeld has no conflicts of interest to declare.Barbara Suwelack has no conflicts of interest to declare .Michael Duerr has received research funds from Bristol–Myers Squibb and travel grants from Novartis and Roche.Martin Zeier has received research funding from Dietmar Hopp-Stiftung.Martina Porstner is an employee of Novartis Pharma GmbH.Eva-Maria Paulus is employee of Novartis Pharma GmbH and holds stock options.Klemens Budde has received research funds and/or honoraria from Abbvie, Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Fresenius, Genentech, Hexal, Novartis, Otsuka, Pfizer, Roche, Shire, Siemens, and Veloxis Pharma.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.